Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | DGKA | P23743 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.34 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.34 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.34 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.34 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.34 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL428467 | 1.00 | MAPT (0.40) | MAPTLMNAKDM4EDUSP3MEN1 | |
| Acetone SCHEMBL2803680 | 0.97 | MAPT (0.38) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL21645267 | 0.89 | MAPT (0.55) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL10795570 | 0.89 | MAPT (0.55) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL21645312 | 0.88 | MAPT (0.58) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL21645269 | 0.88 | MAPT (0.58) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL539662 | 0.88 | MAPT (0.58) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL21645279 | 0.88 | MAPT (0.58) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL10765993 | 0.88 | MAPT (0.58) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL6025493 | 0.88 | MAPT (0.58) | MAPTLMNAKDM4EDUSP3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114317659-B | Preparation method of soybean oligopeptide powder with multiple biological activities | 杭州佳嘉乐生物技术有限公司 | 2024-01-26 | — | — | CN | claimed |
| CN-115590240-A | Preparation method and product of heated cigarette for regulating nicotine slow-release effect | 广东中烟工业有限责任公司（CN） | 2023-01-13 | — | — | CN | claimed |
| CN-114317659-A | Preparation method of soybean oligomeric active peptide powder with multiple biological activities | 杭州佳嘉乐生物技术有限公司 | 2022-04-12 | — | — | CN | claimed |
| US-20080163867-A1 | Molecular Separation Process in Various Steps of Process for Production of Chlorinated Sugars, Their Precursors and Derivatives | V.B. MEDICARE PRIVATE LIMITED (IN) | 2008-07-10 | — | — | US | claimed |
| WO-2006117799-A2 | MOLECULAR SEPARATION PROCESS IN VARIOUS STEPS OF PROCESS FOR PRODUCTION OF CHLORINATED SUGARS, THEIR PRECURSORS AND DERIVATIVES | PHARMED MEDICARE PRIVATE LIMITED (IN) | 2006-11-09 | — | — | WO | claimed |
| US-20250163247-A1 | RESIN COMPOSITION, APPLICATION THEREOF, AND MOLDING METHOD THEREFOR | OSAKA GAS CHEMICALS CO., LTD. (JP) | 2025-05-22 | — | — | US | disclosed |
| CN-118647665-A | Resin composition, use thereof and molding method | 大阪燃气化学有限公司 | 2024-09-13 | — | — | CN | disclosed |
| US-20240110192-A1 | BACTERIA ENGINEERED TO TREAT DISEASES THAT BENEFIT FROM REDUCED GUT INFLAMMATION AND/OR TIGHTENED GUT MUCOSAL BARRIER | SYNLOGIC OPERATING COMPANY, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-11896627-B2 | Bacteria engineered to treat metabolic diseases | SYNLOGIC OPERATING COMPANY, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| CN-114317659-B | Preparation method of soybean oligopeptide powder with multiple biological activities | 杭州佳嘉乐生物技术有限公司 | 2024-01-26 | — | — | CN | disclosed |
| US-11845964-B2 | Bacteria engineered to treat diseases associated with hyperammonemia | SYNLOGIC OPERATING COMPANY, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| WO-2023166943-A1 | RESIN COMPOSITION, APPLICATION THEREOF, AND MOLDING METHOD THEREFOR | 大阪ガスケミカル株式会社 | 2023-09-07 | — | — | WO | disclosed |
| EP-1942869-A2 | CARBOXYALKYL CELLULOSE ESTERS FOR SUSTAINED DELIVERY OF PHARMACEUTICALLY ACTIVE SUBSTANCES | EASTMAN CHEMICAL COMPANY (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007056125-A2 | CARBOXYALKYL CELLULOSE ESTERS FOR SUSTAINED DELIVERY OF PHARMACEUTICALLY ACTIVE SUBSTANCES | EASTMAN CHEMICAL COMPANY (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070104787-A1 | Carboxyalkyl cellulose esters for sustained delivery of pharmaceutically active substances | EASTMAN CHEMICAL COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20040137582-A1 | Methods for manufacturing polysaccharide derivatives | RENSSELAER POLYTECHNIC INSTITUTE | 2004-07-15 | — | — | US | disclosed |
| US-5508182-A | PRODUCING AMPHIPHILIC COMPOUNDS, 1-MONOGLYCERIDES, SUGAR ETERS ON SOLID SUPPORTS USING A HYDROLASE | SCHNEIDER MANFRED P (DE) | 1996-04-16 | — | — | US | disclosed |
| EP-0571421-B1 | ENZYMATIC REVERSE HYDROLYSIS OF HYDROPHILIC SUBSTRATES - PREPARATION OF AMPHIPHILIC COMPOUNDS | SCHNEIDER MANFRED P (DE) | 1995-07-26 | — | — | EP | disclosed |
| EP-0571421-A1 | ENZYMATIC REVERSE HYDROLYSIS OF HYDROPHILIC SUBSTRATES - PREPARATION OF AMPHIPHILIC COMPOUNDS. | SCHNEIDER MANFRED P (DE) | 1993-12-01 | — | — | EP | disclosed |
| WO-1992014830-A1 | ENZYMATIC REVERSE HYDROLYSIS OF HYDROPHILIC SUBSTRATES - PREPARATION OF AMPHIPHILIC COMPOUNDS | SCHNEIDER MANFRED P (DE) | 1992-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845964-B2 | Bacteria engineered to treat diseases associated with hyperammonemia | ASS1, AGXT, OAT | MAPT 1135/4885LMNA 4156/4885KDM4E 3926/4885 |
| US-20040137582-A1 | Methods for manufacturing polysaccharide derivatives | SI, MGAM, IDUA | MAPT 2438/4885LMNA 2907/4885KDM4E 3124/4885 |
| US-20240110192-A1 | BACTERIA ENGINEERED TO TREAT DISEASES THAT BENEFIT FROM REDUCED GUT INFLAMMATION AND/OR TIGHTENED GUT MUCOSAL BARRIER | FABP2, TLR9, LY96 | MAPT 1969/4885LMNA 3923/4885KDM4E 3324/4885 |
| US-20070104787-A1 | Carboxyalkyl cellulose esters for sustained delivery of pharmaceutically active substances | SLC2A1, SLC2A8, SLC2A4 | MAPT 3571/4885LMNA 4523/4885KDM4E 865/4885 |
| US-11896627-B2 | Bacteria engineered to treat metabolic diseases | GOT2, BPGM, MLYCD | MAPT 1558/4885LMNA 2724/4885KDM4E 3339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.